Biosensors & Patches, Explained: The 2026 Field Guide
What biosensors & patches covers, why it matters in 2026, and the numbers decision-makers should know.
Executives keep asking the same question about biosensors & patches. Stretchable patches, biosensor arrays, and on-body diagnostics. This explainer sets out what the category actually covers, why it has moved to the center of wearables & rpm strategy, and the numbers every decision-maker should have at hand.
What it covers
Stretchable patches, biosensor arrays, and on-body diagnostics. In practice, that spans the vendors building the technology, the health systems and payers deploying it, and the regulators writing the rules around it. The category sits inside our broader Wearables & RPM coverage, and its daily developments stream into the live Biosensors & Patches feed.
Why it matters in 2026
Consider the current numbers: oura has sold 5.5 million rings, projects roughly $1.5 billion in 2026 revenue, and has filed confidentially for an IPO (our coverage).
Meanwhile, medicare remote patient monitoring spending has passed $500 million a year, and CMS has proposed consolidating seventeen RPM codes into four by 2027 (our coverage).
Meanwhile, dexcom won authorization for a 15.5-day CGM sensor with 8.0% MARD accuracy (our coverage).
What to watch next
Three signals will tell you where biosensors & patches goes from here: the reimbursement decisions now moving through CMS and commercial payers, the consolidation pattern as larger platforms absorb point solutions, and the evidence base - peer-reviewed results increasingly separate durable categories from demo-ware.
The bottom line
The direction of travel is clear; the pace will be set by reimbursement and by the evidence base now accumulating. For the latest developments, follow our continuously updated Biosensors & Patches topic page.